Tyme Technologies, Inc. (NASDAQ:TYME) COO Michael Demurjian sold 50,000 shares of the stock in a transaction on Tuesday, November 14th. The shares were sold at an average price of $3.34, for a total value of $167,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Tyme Technologies, Inc. (NASDAQ TYME) traded up $0.27 during midday trading on Friday, hitting $4.00. 559,051 shares of the stock were exchanged, compared to its average volume of 109,972. Tyme Technologies, Inc. has a 1-year low of $1.01 and a 1-year high of $9.50.

ILLEGAL ACTIVITY NOTICE: This piece was originally published by Watch List News and is owned by of Watch List News. If you are accessing this piece on another site, it was stolen and reposted in violation of United States and international trademark & copyright legislation. The correct version of this piece can be accessed at https://www.watchlistnews.com/tyme-technologies-inc-tyme-coo-michael-demurjian-sells-50000-shares/1712370.html.

Separately, Evercore ISI initiated coverage on Tyme Technologies in a report on Friday. They issued an “outperform” rating and a $7.00 target price for the company.

Tyme Technologies Company Profile

Tyme Technologies, Inc is a clinical-stage biotechnology company. The Company is focused on developing cancer therapeutics that is intended to be broadly effective across tumor types and have low toxicity profiles. The Company’s therapeutic approach is designed to take advantage of a cancer cell’s innate metabolic weaknesses to compromise its defenses, leading to cell death through oxidative stress and exposure to the body’s natural immune system.

Receive News & Ratings for Tyme Technologies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tyme Technologies Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.